Evaluation and analysis of patients presenting neurodegenerative dementia or parkinsonism with [18F]THK-5351 positron emission tomography

Evaluation and analysis of patients presenting neurodegenerative dementia or parkinsonism with [18F]THK-5351 positron emission tomography - Evaluation and analysis of patients presenting neurodegenerative disease with [18F]THK-5351 PET

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018496

Enrollment

220

Registered

2015-08-01

Start date

2015-11-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mild cognitive impairment(MCI),Alzheimer-type dementia(AD), frontotemporal dementia(FTD), corticobasal degeneration(CBD),progressive supranuclear palsy(PSP),Parkinson&#39

Interventions

We use [18F]THK-5351 as tau radiotracer by administration intravenously.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: each disease;20 healthy control;40

Exclusion criteria

Exclusion criteria: Persons who several doctors think it is difficult participate the trial.

Design outcomes

Primary

Measure	Time frame
About each neurodegenerative disease,We compare [18F]THK-5351 PET imaging with MRI and clnical syndrome.	—

Countries

Japan

Contacts

Public ContactTakamasa Yokoi

Nagoya University Department of Neurology

tayokoi@med.nagoya-u.ac.jp052-744-1975

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026